Penn study demonstrates that engineered macrophages, which can be targeted to tumors, may be a possible new immune-based treatment of some cancers. Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which...